Literature DB >> 18718497

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.

Xiaohong Cui1, Benjamin P Meza, Stuart P Adler, Michael A McVoy.   

Abstract

Antibodies that neutralize cytomegalovirus (CMV) entry into fibroblasts are predominantly directed against epitopes within virion glycoproteins that are required for attachment and entry. However, the mechanism of CMV entry into epithelial and endothelial cells differs from fibroblast entry. Using assays that simultaneously measured neutralizing activities against CMV entry into fibroblasts and epithelial cells, we found that human immune sera and CMV-hyperimmuneglobulins have on on average 48-fold higher neutralizing activities against epithelial cell entry compared to fibroblast entry, suggesting that natural CMV infections elicit neutralizing antibodies that are epithelial entry-specific. This activity could not be adsorbed with recombinant gB. The Towne vaccine and the gB/MF59 subunit vaccine induced epithelial entry-specific neutralizing activities that were on on average 28-fold (Towne) or 15-fold (gB/MF59) lower than those observed following natural infection. These results suggest that CMV vaccine efficacy may be enhanced by the induction of epithelial entry-specific neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718497      PMCID: PMC2583261          DOI: 10.1016/j.vaccine.2008.07.092

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

1.  Role of human cytomegalovirus UL131A in cell type-specific virus entry and release.

Authors:  Barbara Adler; Laura Scrivano; Zsolt Ruzcics; Brigitte Rupp; Christian Sinzger; Ulrich Koszinowski
Journal:  J Gen Virol       Date:  2006-09       Impact factor: 3.891

2.  Passive immunization during pregnancy for congenital cytomegalovirus infection.

Authors:  Giovanni Nigro; Stuart P Adler; Renato La Torre; Al M Best
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

3.  Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.

Authors:  Dai Wang; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-30       Impact factor: 11.205

4.  Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response.

Authors:  Masako Shimamura; Michael Mach; William J Britt
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 5.  Entry route of HCMV into endothelial cells.

Authors:  Christian Sinzger
Journal:  J Clin Virol       Date:  2008-01-18       Impact factor: 3.168

6.  Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection.

Authors:  Giuseppe Gerna; Antonella Sarasini; Marco Patrone; Elena Percivalle; Loretta Fiorina; Giulia Campanini; Andrea Gallina; Fausto Baldanti; M Grazia Revello
Journal:  J Gen Virol       Date:  2008-04       Impact factor: 3.891

7.  Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells.

Authors:  Dai Wang; Qian-Chun Yu; Jörg Schröer; Eain Murphy; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-05       Impact factor: 11.205

8.  Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.

Authors:  Brent J Ryckman; Barb L Rainish; Marie C Chase; Jamie A Borton; Jay A Nelson; Michael A Jarvis; David C Johnson
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

9.  Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells.

Authors:  Marco Patrone; Massimiliano Secchi; Eleonora Bonaparte; Gabriele Milanesi; Andrea Gallina
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

10.  Novel microneutralization assay for HCMV using automated data collection and analysis.

Authors:  Anna Maria Abai; Larry R Smith; Mary K Wloch
Journal:  J Immunol Methods       Date:  2007-02-23       Impact factor: 2.303

View more
  92 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

3.  Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Authors:  Xiaohong Cui; Stuart P Adler; Mark R Schleiss; Ravit Arav-Boger; Gail J Demmler Harrison; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 4.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

5.  Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta.

Authors:  Takako Tabata; Matthew Petitt; June Fang-Hoover; Martin Zydek; Lenore Pereira
Journal:  Am J Pathol       Date:  2016-09-13       Impact factor: 4.307

6.  Humoral Immune Correlates for Prevention of Postnatal Cytomegalovirus Acquisition.

Authors:  Frances M Saccoccio; Jennifer A Jenks; Hannah L Itell; Shuk Hang Li; Madison Berry; Justin Pollara; Corey Casper; Soren Gantt; Sallie R Permar
Journal:  J Infect Dis       Date:  2019-07-31       Impact factor: 5.226

7.  In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.

Authors:  Hetalkumar D Patel; Pavel Nikitin; Thomas Gesner; James J Lin; David T Barkan; Claudio Ciferri; Andrea Carfi; Tahmineh Akbarnejad Yazdi; Peter Skewes-Cox; Brigitte Wiedmann; Nadine Jarousse; Weidong Zhong; Adam Feire; Christy M Hebner
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

8.  Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.

Authors:  Mark R Schleiss; Craig J Bierle; Elizabeth C Swanson; Michael A McVoy; Jian Ben Wang; Zainab Al-Mahdi; Adam P Geballe
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

9.  Requirements for guinea pig cytomegalovirus tropism and antibody neutralization on placental amniotic sac cells.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2020-02-18       Impact factor: 3.891

10.  A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.

Authors:  Stuart P Adler; Anne-Marie Manganello; Ronzo Lee; Michael A McVoy; Daniel E Nixon; Stanley Plotkin; Edward Mocarski; Josephine H Cox; Patricia E Fast; Pavlo A Nesterenko; Susan E Murray; Ann B Hill; George Kemble
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.